Reduced IL-33 plasma levels in aplastic anemia.
Ming Sun1, Hai-Feng Ma1, Ye-Yun Che1
1Department of Hematology, Linzi District People's Hospital, Zibo, 255400 China.
Cancer Cell International
|December 18, 2015
Summary
Interleukin-33 (IL-33) and its receptor sST2 balance is altered in aplastic anemia (AA). Active AA shows higher sST2 and lower IL-33, suggesting a role in disease progression.
Area of Science:
- Hematology
- Immunology
- Molecular Biology
Background:
- Aplastic anemia (AA) is a rare bone marrow failure disorder.
- The role of specific cytokines, like IL-33 and its receptor sST2, in AA pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the balance of interleukin-33 (IL-33) and its soluble receptor sST2 in patients with aplastic anemia (AA).
- To assess the levels of IL-17 in conjunction with IL-33 and sST2 in AA patients.
Main Methods:
- Plasma samples from active AA (n=31), remission AA (n=29), and healthy controls (n=30) were analyzed.
- Enzyme-linked immunosorbent assays (ELISAs) were used to quantify IL-33, IL-17, and sST2 levels.
Main Results:
- Patients with active AA exhibited significantly elevated sST2 and IL-17 levels compared to healthy controls.
- Conversely, IL-33 levels were significantly lower in active AA patients, leading to increased sST2/IL-33 ratios.
- Cytokine levels in AA remission patients were comparable to those of healthy controls.
Conclusions:
- The elevated sST2/IL-33 ratio in active AA suggests a potential involvement in the disease's pathogenesis and progression.
- These findings highlight the IL-33/sST2 axis as a potential biomarker and therapeutic target in aplastic anemia.
